55 related articles for article (PubMed ID: 20010076)
1. Optimal equations for describing the relationship between prostate volume, number of sources, and total activity in permanent prostate brachytherapy.
Aronowitz JN; Michalski JM; Merrick GS; Sylvester JE; Crook JM; Butler WM; Mawson C; Pratt D; Naidoo D; Karolczuk K
Am J Clin Oncol; 2010 Apr; 33(2):164-7. PubMed ID: 20010076
[TBL] [Abstract][Full Text] [Related]
2. Inter-institutional variation of implant activity for permanent prostate brachytherapy.
Aronowitz JN; Crook JM; Michalski JM; Sylvester JE; Merrick GS; Mawson C; Pratt D; Naidoo D; Butler WM; Karolczuk K
Brachytherapy; 2008; 7(4):297-300. PubMed ID: 18786866
[TBL] [Abstract][Full Text] [Related]
3. A study of a pretreatment method to predict the number of I-125 seeds required for prostate brachytherapy.
Al-Qaisieh B; Brearley E; St Clair S; Flynn A
Int J Radiat Oncol Biol Phys; 2006 May; 65(1):304-7. PubMed ID: 16618585
[TBL] [Abstract][Full Text] [Related]
4. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
[TBL] [Abstract][Full Text] [Related]
5. Factors predicting for urinary incontinence after prostate brachytherapy.
McElveen TL; Waterman FM; Kim H; Dicker AP
Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
[TBL] [Abstract][Full Text] [Related]
6. An innovative dosimetric model for formulating a semi-analytical solution for the activity-volume relationship in prostate implants.
Lee PC; Parks EK; Moran BJ
Med Dosim; 2003; 28(4):243-53. PubMed ID: 14684189
[TBL] [Abstract][Full Text] [Related]
7. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
[TBL] [Abstract][Full Text] [Related]
8. Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry.
Su Y; Davis BJ; Furutani KM; Herman MG; Robb RA
Phys Med Biol; 2007 Jun; 52(11):3105-19. PubMed ID: 17505092
[TBL] [Abstract][Full Text] [Related]
9. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
Dicker AP; Lin CC; Leeper DB; Waterman FM
Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
[TBL] [Abstract][Full Text] [Related]
10. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
[TBL] [Abstract][Full Text] [Related]
11. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
Pickett B; Pouliot J
Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
[TBL] [Abstract][Full Text] [Related]
12. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
[TBL] [Abstract][Full Text] [Related]
13. Comparison of MRI- and CT-based post-implant dosimetric analysis of transperineal interstitial permanent prostate brachytherapy.
Prete JJ; Prestidge BR; Bice WS; Dubois DF; Hotchkiss LA
Radiat Oncol Investig; 1998; 6(2):90-6. PubMed ID: 9572685
[TBL] [Abstract][Full Text] [Related]
14. Dose-volume conundrum for response of prostate cancer to brachytherapy: summary dosimetric measures and their relationship to tumor control probability.
D'Souza WD; Thames HD; Kuban DA
Int J Radiat Oncol Biol Phys; 2004 Apr; 58(5):1540-8. PubMed ID: 15050335
[TBL] [Abstract][Full Text] [Related]
15. Morbidity effect of the time gap between supplemental beam radiation and Pd-103 prostate brachytherapy.
Corriveau J; Wallner K; Merrick G; True L; Cavanagh W; Sutlief S; Butler W
Brachytherapy; 2003; 2(2):108-13. PubMed ID: 15062149
[TBL] [Abstract][Full Text] [Related]
16. Excellent results from high dose rate brachytherapy and external beam for prostate cancer are not improved by androgen deprivation.
Demanes DJ; Brandt D; Schour L; Hill DR
Am J Clin Oncol; 2009 Aug; 32(4):342-7. PubMed ID: 19398902
[TBL] [Abstract][Full Text] [Related]
17. Natural history of clinically staged low- and intermediate-risk prostate cancer treated with monotherapeutic permanent interstitial brachytherapy.
Taira AV; Merrick GS; Galbreath RW; Wallner KE; Butler WM
Int J Radiat Oncol Biol Phys; 2010 Feb; 76(2):349-54. PubMed ID: 19467793
[TBL] [Abstract][Full Text] [Related]
18. Results of permanent prostate brachytherapy, 13 years of experience at a single institution.
Battermann JJ; Boon TA; Moerland MA
Radiother Oncol; 2004 Apr; 71(1):23-8. PubMed ID: 15066292
[TBL] [Abstract][Full Text] [Related]
19. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
[TBL] [Abstract][Full Text] [Related]
20. Is an 192Ir permanent seed implant feasible for prostate brachytherapy?
Glasgow GP; Dogan N; Mohideen N
Brachytherapy; 2002; 1(4):195-203. PubMed ID: 15062167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
